|Bid||169.04 x 800|
|Ask||169.16 x 800|
|Day's Range||167.18 - 169.74|
|52 Week Range||119.38 - 188.65|
|Beta (3Y Monthly)||1.09|
|PE Ratio (TTM)||19.23|
|Earnings Date||Jul 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||178.11|
LabCorp® (LH) will release its second quarter of 2019 financial results before the market opens on Thursday, July 25, 2019, followed by a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results. Interested parties can access the conference call by dialing 844-634-1444 within the U.S. and Canada, or 1-615-247-0253 internationally, using the passcode 9679477. An audio replay of the conference call will be available from 1:00 p.m. EDT on July 25, 2019, until 11:30 a.m. EDT on August 8, 2019, by dialing 855-859-2056 within the U.S. and Canada, or 1-404-537-3406 internationally, using the passcode 9679477.
Challenging market conditions, especially in retail, causes a slowdown in the Retail Pharmacy International division at Walgreens Boots (WBA).
The artificial intelligence being shared with New York City's largest health system, Mount Sinai, has already been implemented in four of LabCorp's laboratories.
LabCorp® (LH) and the Mount Sinai Health System today announced another element in their shared goal of improving laboratory services and patient care. LabCorp, a leading global life sciences company, and Mount Sinai, New York City's largest integrated healthcare delivery system, will work together to establish the Mount Sinai Digital and Artificial Intelligence (AI)-Enabled Pathology Center of Excellence.
LabCorp's (LH) Diagnostics business sees an organic uptick in terms of both revenues and volumes in spite of further price reductions.
Zacks.com featured highlights include: Starbucks, T. Rowe Price, Laboratory Corporation, Carlisle and FleetCor
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
Laboratory Corporation of America Holdings NYSE:LHView full report here! Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for LH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting LH. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold LH had net inflows of $3.71 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. LH credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
LabCorp® (LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced a new companion diagnostic called therascreen® PIK3CA PCR mutation analysis, which is now available through LabCorp and its Integrated Oncology specialty laboratory. The test, developed by QIAGEN (NYSE: QGEN, Frankfurt Stock Exchange: QIA), a world leader in Sample to Insight solutions for molecular testing, identifies whether a patient has the specific gene mutation that is a prerequisite for treatment with Piqray® (aplelisib), a new therapy from Novartis for the treatment of postmenopausal women and all men with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-), PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
NEW YORK , June 6, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential misconduct at Laboratory Corporation of America Holdings ("LabCorp" ...
Opko Health Inc said on Thursday it was notified by its former billing collections vendor about unauthorized access to information on about 422,600 customers, making it the third healthcare company to be affected by the incident. American Medical Collection Agency (AMCA) informed Opko Health that the compromised data may include credit card and bank account information, email addresses and other data such as address, phone number and balance information. Earlier this week, rivals Quest Diagnostics Inc and Laboratory Corporation of America Holdings also announced that they were apprised of unauthorized access to their customer data stored on AMCA system.
On Wednesday, King announced his retirement as president and CEO of the Burlington-based life sciences firm.
The Daily Crunch is TechCrunch's roundup of our biggest and most important stories. The company, which has been valued at $4 billion, paved the way for a variety of home fitness companies. YouTube has told a reporter at Vox that the comments made by a prominent conservative channel (describing the reporter as as "lispy queer" and "the gay Latino host at Vox") do not violate its policies.
LabCorp is the latest laboratory testing giant this week to confirm it'saffected by the same third-party data breach
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...
LabCorp® (LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that David P. King, its chairman, president and CEO, will become executive chairman of the board of directors on Nov. 1, retiring Oct. 31 as president and CEO. Adam H. Schechter, current lead independent director of LabCorp’s board and former Merck executive vice president and president of global human health, will become president and CEO on Nov. 1.
The conclusion of LabCorp's (LH) swap transaction will help enhance the company's Covance global nonclinical drug development capabilities with additional sites and resources.
On June 3, 2019, LabCorp® (LH) entered into a new Term Loan Credit Agreement, which provides for a two-year term loan credit facility in the principal amount of $850 million (the “New Term Loan Facility”). Bank of America, N.A. is acting as administrative agent for a group of financial institutions providing the New Term Loan Facility. The proceeds from the borrowings under the New Term Loan Facility will be used for general corporate purposes, including to repay other indebtedness and in connection with the previously announced acquisition of the nonclinical research services business of Envigo International Holdings, Inc. (“Envigo”).
LabCorp® (LH), a leading global life sciences company that is deeply integrated in guiding patient care, and Envigo, a leading provider of research models and services, today announced that they have completed previously announced transactions that will strengthen and enhance the way their respective businesses support research in the biopharmaceutical and life sciences industries.